Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Fiorentina are set to win the race to sign Inter Milan striker Sebastiano Esposito ahead of Cagliari and Hellas Verona.This ...

Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Fintel reports that on July 10, 2025, BTIG downgraded their outlook for Verona Pharma plc - Depositary Receipt () ...

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...

Matilde Pavan has joined Juventus Women, with the midfielder joining the Bianconere from Inter ahead of the 2025/26 Serie A ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Find insight on Merck, RxSight, and more in the latest Market Talks covering Health Care.